Abstract

Mefenamic acid (MFA) has been used as a pain reliever for a long time. However, as a Biopharmaceutics Classification System II drug, the low solubility remains a major issue. Recently an article has featured the efforts in generating amorphous solid dispersions of MFA for topical administration. Despite the novelty and some successful results from the polyvinylpyrrolidone dispersions, there are a few key points that are worth a thorough discussion, including the experimental methodology for the characterization, evaluation of the physical stability, and data interpretation for the drug release.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.